Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mengting Dong, Su Jiang, Wenyan Tian, Ye Yan, Chao Gao, Jinping Gao, Yan Sheng, Yingmei Wang & Fengxia Xue. (2018) Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review. Cancer Biology & Therapy 19:11, pages 956-961.
Read now
Read now
Ivana Šestak & Jack Cuzick. (2016) Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. Expert Review of Endocrinology & Metabolism 11:5, pages 425-432.
Read now
Read now
Marguerite Palisoul & David G Mutch. (2016) The clinical management of inoperable endometrial carcinoma. Expert Review of Anticancer Therapy 16:5, pages 515-521.
Read now
Read now
Gokalp Oner, Bulent Ozcelik, Mahmut Tuncay Ozgun & Figen Ozturk. (2011) The effects of metformin and letrozole on endometrium and ovary in a rat model. Gynecological Endocrinology 27:12, pages 1084-1086.
Read now
Read now
Helen L Steed & Quincy S-C Chu. (2011) Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?. Expert Opinion on Investigational Drugs 20:5, pages 681-690.
Read now
Read now
Articles from other publishers (27)
Giuseppina Porcaro, Gabriele Bilotta, Elena Capoccia, Maria Salomé Bezerra Espinola & Cesare Aragona. (2023) D-Chiro-Inositol in Endometrial Hyperplasia: A Pilot Study. International Journal of Molecular Sciences 24:12, pages 10080.
Crossref
Crossref
Nadeem Abu-Rustum, Catheryn Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli, Ernest Han, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole R. McMillian & Shaili Aggarwal. (2023) Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 21:2, pages 181-209.
Crossref
Crossref
Junyu Chen, Dongyan Cao, Jiaxin Yang, Mei Yu, Huimei Zhou, Ninghai Cheng, Jinhui Wang, Ying Zhang, Peng Peng & Keng Shen. (2022) Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia. International Journal of Gynecologic Cancer 32:12, pages 1561-1567.
Crossref
Crossref
Aparna Kailasam & Carrie Langstraat. (2022) Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review. Current Treatment Options in Oncology 23:12, pages 1818-1828.
Crossref
Crossref
Seval AY, Özgecan DÜLGAR & Hüseyin KANMAZ. (2022) Prognostic Role of Hormone Status in Endometrium CancerEndometrium kanserinde hormon reseptölerinin prognostik önemi. Turkish Journal of Clinics and Laboratory 13:3, pages 397-401.
Crossref
Crossref
Ying Shan, Meng Qin, Jie Yin, Yan Cai, Yan Li, Yu Gu, Wei Wang, Yong-xue Wang, Jia-yu Chen, Ying Jin & Ling-ya Pan. (2021) Effect and Management of Excess Weight in the Context of Fertility-Sparing Treatments in Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer: Eight-Year Experience of 227 Cases. Frontiers in Oncology 11.
Crossref
Crossref
Seung-Hyuk Shim, Su Hyun Chae, Kyeong A So, Sun Joo Lee, Ji Young Lee, Tae Jin Kim, Ernest S. Han & Soon-Beom Kang. (2021) Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer. Gynecologic Oncology 161:3, pages 810-816.
Crossref
Crossref
Linda Mileshkin, Richard Edmondson, Rachel L. O'Connell, Katrin M. Sjoquist, John Andrews, Rema Jyothirmayi, Philip Beale, Tony Bonaventura, Jeffrey Goh, Marcia Hall, Andrew Clamp, John Green, Rosemary Lord, Frédéric Amant, Laura Alexander, Karen Carty, James Paul, James Scurry, David Millan, Steven Nottley & Michael Friedlander. (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology 154:1, pages 29-37.
Crossref
Crossref
K.M.C. Cornel, M.Y. Bongers, R.P.F.M. Kruitwagen & A. Romano. (2019) Local estrogen metabolism (intracrinology) in endometrial cancer: A systematic review. Molecular and Cellular Endocrinology 489, pages 45-65.
Crossref
Crossref
Zhibo Zhang, Huifang Huang, Fengzhi Feng, Jinhui Wang & Ninghai Cheng. (2019) A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. Journal of Gynecologic Oncology 30:4.
Crossref
Crossref
Huimei Zhou, Dongyan Cao, Jiaxin Yang, Keng Shen & Jinghe Lang. (2017) Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. International Journal of Gynecologic Cancer 27:6, pages 1178-1182.
Crossref
Crossref
Seema Patel. (2017) Fragrance compounds: The wolves in sheep’s clothings. Medical Hypotheses 102, pages 106-111.
Crossref
Crossref
Sanam Moradan, Niaz Nikkhah & Majid Mirmohammadkhanai. (2017) Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial. Advances in Therapy 34:5, pages 1211-1220.
Crossref
Crossref
Dylan M. Glubb, Tracy A. O'Mara, Jannah Shamsani & Amanda B. Spurdle. (2017) The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?. Frontiers in Pharmacology 8.
Crossref
Crossref
Chong Hyun Suh, Sree H Tirumani, Abhishek Keraliya, Kyung Won Kim, Nikhil H Ramaiya & Atul B Shinagare. (2016) Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. The British Journal of Radiology 89:1066, pages 20160086.
Crossref
Crossref
Alessandra Cerávolo Lara, Eduardo Batista Cândido, Paula Vieira Vidigal, Ana Luiza Lunardi Rocha, Alessandra Costa Carvalho-Macedo, Márcia Mendonça Carneiro & Agnaldo Lopes Silva-Filho. (2016) Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice. Acta Cirurgica Brasileira 31:4, pages 286-293.
Crossref
Crossref
Stefano Bogliolo, Barbara Gardella, Mattia Dominoni, Valentina Musacchi, Chiara Cassani, Francesca Zanellini, Annalisa De Silvestri, Chiara Roberta Gaggero, Luciana Babilonti & Arsenio Spinillo. (2015) Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. Archives of Gynecology and Obstetrics 293:4, pages 701-708.
Crossref
Crossref
Areege Kamal, Nicola Tempest, Christina Parkes, Rafah Alnafakh, Sofia Makrydima, Meera Adishesh & Dharani K. Hapangama. (2016) Hormones and endometrial carcinogenesis. Hormone Molecular Biology and Clinical Investigation 25:2, pages 129-148.
Crossref
Crossref
Vishal Chandra, Jong Joo Kim, Doris Mangiaracina Benbrook, Anila Dwivedi & Rajani Rai. (2016) Therapeutic options for management of endometrial hyperplasia. Journal of Gynecologic Oncology 27:1.
Crossref
Crossref
Won Moo LeeKi-Seok JangJaeman BaeA Ra Koh. (2016) The Role of Steroid Sulfatase as a Prognostic Factor in Patients with Endometrial Cancer. Yonsei Medical Journal 57:3, pages 754.
Crossref
Crossref
Pan-Lin Zhao, Qiu-Fang Zhang, Li-Ying Yan, Shuo Huang, Yuan Chen & Jie Qiao. (2014) Functional Investigation on Aromatase in Endometrial Hyperplasia in Polycystic Ovary Syndrome Cases. Asian Pacific Journal of Cancer Prevention 15:20, pages 8975-8979.
Crossref
Crossref
Chao Gao, Yingmei Wang, Wenyan Tian, Yuanxi Zhu & Fengxia Xue. (2014) The therapeutic significance of aromatase inhibitors in endometrial carcinoma. Gynecologic Oncology 134:1, pages 190-195.
Crossref
Crossref
Amudha Thangavelu, Matthew J. Hewitt, Naomi D. Quinton & Sean R. Duffy. (2013) Neoadjuvant treatment of endometrial cancer using anastrozole: A randomised pilot study. Gynecologic Oncology 131:3, pages 613-618.
Crossref
Crossref
Lloyd H. Smith, Gary Leiserowitz, Guibo Xing & John Bishop. (2013) Short-term Femara (letrozole) treatment and suppression of Ki67 expression in postmenopausal endometrial carcinoma. Open Journal of Obstetrics and Gynecology 03:03, pages 347-351.
Crossref
Crossref
Alon D. Altman, Gregg S. Nelson, Pamela Chu, Jill Nation & Prafull Ghatage. (2012) Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature. International Journal of Gynecologic Cancer 22:6, pages 1006-1012.
Crossref
Crossref
Alon D. Altman, Jennifer Thompson, Gregg Nelson, Pamela Chu, Jill Nation & Prafull Ghatage. (2012) Use of Aromatase Inhibitors as First-and Second-Line Medical Therapy in Patients With Endometrial Adenocarcinoma: A Retrospective Study. Journal of Obstetrics and Gynaecology Canada 34:7, pages 664-672.
Crossref
Crossref
M. El-shamy, A. Gibreel, E. Refai, E. Sadek & A. Ragab. (2012) Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial. Middle East Fertility Society Journal 17:2, pages 111-115.
Crossref
Crossref